Richard J Monaghan

US Patent:

45307903, Jul 23, 1985

Filed:

Jul 1, 1983

Appl. No.:

6/509883

Inventors:

Richard L. Monaghan - Somerset NJ
Michael A. Goetz - Fanwood NJ
Raymond S. L. Chang - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D51900
A61K 3155
C12P 1718
C12R 166

US Classification:

2602393P

Abstract:

The compound having Formula I and several minor related compounds are produced by the aerobic fermentation of Aspergillus alliaceus Thom and Church, ATCC No. 20655 or ATCC No. 20656. ##STR1## The compound of Formula I and the several minor related compounds are antagonists of cholecystokinin (CCK). CCK antagonists are useful in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals, especially humans.

US Patent:

48289922, May 9, 1989

Filed:

Feb 3, 1986

Appl. No.:

6/825497

Inventors:

Sagrario M. Del Val - Madrid, ES
Maria I. M. Fernandez - Madrid, ES
Richard L. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 1702
C12P 740
C12N 114
C12R 177

US Classification:

435123

Abstract:

The process for the manufacture of the compound of the general structural formula ##STR1## which is a 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) synthase inhibitor and useful as an antihypercholesterolemic agent for the treatment of disease in which the inhibition of cholesterol biosynthesis would be useful, and which is an antifungal agent is disclosed.

US Patent:

53188950, Jun 7, 1994

Filed:

Oct 5, 1992

Appl. No.:

7/956716

Inventors:

Jennifer N. Kahn - East Brunswick NJ
Kevin M. Byrne - West Trenton NJ
Louis Kaplan - New City NY
Richard J. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 118
C12N 100
C07D49800

US Classification:

435 32

Abstract:

Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.

US Patent:

42949262, Oct 13, 1981

Filed:

Jan 23, 1980

Appl. No.:

6/114458

Inventors:

Richard L. Monaghan - Somerset NJ
Alfred W. Alberts - Short Hills NJ
Carl H. Hoffman - Scotch Plains NJ
George Albers-Schonberg - Princeton NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 726
C12P 1706

US Classification:

435125

Abstract:

Substances isolated after cultivation of a microorganism belonging to the genus Aspergillus in a culture medium comprise a compound designated MSD803 which has the lactone structure: ##STR1## as well as its free hydroxy acid form. Together with salts and esters of the free acid form, these compounds form a class of highly active hypocholesteremic and hypolipemic medicaments.

US Patent:

42319382, Nov 4, 1980

Filed:

Jun 15, 1979

Appl. No.:

6/048946

Inventors:

Richard L. Monaghan - Somerset NJ
Alfred W. Alberts - Short Hills NJ
Carl H. Hoffman - Scotch Plains NJ
George Albers-Schonberg - Princeton NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D30930

US Classification:

2603435

Abstract:

Substances isolated after cultivation of a microorganism belonging to the genus Aspergillus in a culture medium comprise a compound designated MSD803 which has the lactone structure: ##STR1## as well as its free hydroxy acid form. Together with salts and esters of the free acid form, these compounds form a class of highly active hypocholesteremic and hypolipemic medicaments.

US Patent:

46955445, Sep 22, 1987

Filed:

Mar 15, 1985

Appl. No.:

6/712046

Inventors:

Richard L. Monaghan - Somerset NJ
Michael A. Goetz - Fanwood NJ
Raymond S. Chang - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 114
C12P 1718
C12R 166

US Classification:

435119

Abstract:

A process for preparing the compound having Formula I and several minor related compounds. ##STR1## The compound of Formula I and the several minor related compounds are antagonists of cholecystokinin (CCK). CCK antagonists are useful in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals, especially humans.

US Patent:

45405751, Sep 10, 1985

Filed:

May 6, 1983

Appl. No.:

6/492272

Inventors:

Richard L. Monaghan - Somerset NJ
Yu-Lin Kong - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3574
C12P 106

US Classification:

424115

Abstract:

New fermentation products useful in the treatment of tardive dyskinesia by inhibition of choline oxidase are produced by fermentation of a nutrient medium with a microorganism, Streptomyces hygroscopicus.

US Patent:

52783200, Jan 11, 1994

Filed:

Sep 11, 1992

Appl. No.:

7/943661

Inventors:

Richard L. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D40512
C07D40712

US Classification:

549 60

Abstract:

Compounds of Structural Formula (I) ##STR1## are produced by chemical modification of directed biosynthesis products. These compounds are squalene synthetase inhibitors and thus useful as cholesterol lowering agents, antifungal agents and cancer treatment agents.